US Patent

US12295935 — Method for therapeutic treatment of rosacea

Method of Use · Assigned to Sol Gel Technologies Ltd · Expires 2040-12-27 · 15y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method for treating a skin condition or affliction using a pharmaceutical composition containing benzoyl peroxide.

USPTO Abstract

A regimen and a pharmaceutical composition for the treatment of a skin condition and/or skin affliction are described. The regimen includes topically applying to the skin of a subject in need of such treatment a pharmaceutical composition comprising about 2.5% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient.

Drugs covered by this patent

Benzamycin (BENZOYL PEROXIDE) · Mayne Pharma

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3356`	—	Benzamycin
`U-3987`	—	Benzamycin

Patent Metadata

Patent number: US12295935
Jurisdiction: US
Classification: Method of Use
Expires: 2040-12-27
Drug substance claim: No
Drug product claim: No
Assignee: Sol Gel Technologies Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.